80 FR 75867 - Determination That OPHTHAINE (proparacaine hydrochloride) Solution and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 80, Issue 233 (December 4, 2015)

The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

[Federal Register Volume 80, Number 233 (Friday, December 4, 2015)]
[Notices]
[Pages 75867-75868]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-30628]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-4399]


Determination That OPHTHAINE (proparacaine hydrochloride) 
Solution and Other Drug Products Were Not Withdrawn From Sale for 
Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) has 
determined that the drug products listed in this document were not 
withdrawn from sale for reasons of safety or effectiveness. This 
determination means

[[Page 75868]]

that FDA will not begin procedures to withdraw approval of abbreviated 
new drug applications (ANDAs) that refer to these drug products, and it 
will allow FDA to continue to approve ANDAs that refer to the products 
as long as they meet relevant legal and regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 51, Rm. 6236, Silver Spring, MD 20993-0002, 301-796-8363, 
[email protected].

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price 
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) 
(the 1984 amendments), which authorized the approval of duplicate 
versions of drug products approved under an ANDA procedure. ANDA 
applicants must, with certain exceptions, show that the drug for which 
they are seeking approval contains the same active ingredient in the 
same strength and dosage form as the ``listed drug,'' which is a 
version of the drug that was previously approved. ANDA applicants do 
not have to repeat the extensive clinical testing otherwise necessary 
to gain approval of a new drug application (NDA).
    The 1984 amendments include what is now section 505(j)(7) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which 
requires FDA to publish a list of all approved drugs. FDA publishes 
this list as part of the ``Approved Drug Products With Therapeutic 
Equivalence Evaluations,'' which is generally known as the ``Orange 
Book.'' Under FDA regulations, a drug is removed from the list if the 
Agency withdraws or suspends approval of the drug's NDA or ANDA for 
reasons of safety or effectiveness, or if FDA determines that the 
listed drug was withdrawn from sale for reasons of safety or 
effectiveness (21 CFR 314.162).
    Under Sec.  314.161(a) (21 CFR 314.161(a)), the Agency must 
determine whether a listed drug was withdrawn from sale for reasons of 
safety or effectiveness: (1) Before an ANDA that refers to that listed 
drug may be approved, (2) whenever a listed drug is voluntarily 
withdrawn from sale and ANDAs that refer to the listed drug have been 
approved, and (3) when a person petitions for such a determination 
under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if 
FDA determines that a listed drug was withdrawn from sale for safety or 
effectiveness reasons, the Agency will initiate proceedings that could 
result in the withdrawal of approval of the ANDAs that refer to the 
listed drug.
    FDA has become aware that the drug products listed in the table in 
this document are no longer being marketed.

------------------------------------------------------------------------
    Application No.                Drug                  Applicant
------------------------------------------------------------------------
NDA 008883.............  OPHTHAINE (proparacaine  Apothecon, Inc.
                          hydrochloride)
                          Solution/Drops;
                          Ophthalmic, 0.5%.
NDA 009053.............  PURINETHOL               Teva Pharmaceuticals
                          (mercaptopurine)         USA.
                          Tablet; Oral, 50
                          milligrams (mg).
NDA 012427.............  DIDREX (benzphetamine    Pharmacia & Upjohn Co.
                          hydrochloride) Tablet;
                          Oral, 50 mg.
NDA 012583.............  OPHTHETIC (proparacaine  Allergan
                          hydrochloride)           Pharmaceutical.
                          Solution/Drops;
                          Ophthalmic, 0.5%.
NDA 017716.............  OVCON-35 (ethinyl        Warner Chilcott LLC.
                          estradiol;
                          norethindrone) Tablet;
                          Oral-28, 0.035 mg; 0.4
                          mg.
NDA 018782.............  NORDETTE-28 (ethinyl     Teva Branded
                          estradiol;               Pharmaceutical
                          levonorgestrel)          Products R and D,
                          Tablet; Oral-28, 0.03    Inc.
                          mg; 0.15 mg.
NDA 021199.............  QUIXIN (levofloxacin)    Santen, Inc.
                          Solution/Drops;
                          Ophthalmic, 0.5%.
NDA 021595.............  SANCTURA (trospium       Allergan, Inc.
                          chloride) Tablet;
                          Oral, 20 mg.
NDA 021664.............  BROMDAY (bromfenac       Bausch & Lomb, Inc.
                          sodium) Solution/
                          Drops; Ophthalmic, EQ
                          0.09% acid.
NDA 022103.............  SANCTURA XR (trospium    Allergan, Inc.
                          chloride) Extended-
                          Release Capsule; Oral,
                          60 mg.
ANDA 060571............  MYCOSTATIN (nystatin)    Delcor Asset Corp.
                          Ointment; Topical,
                          100,000 units/gram (g).
ANDA 060575............  MYCOSTATIN (nystatin)    Do.
                          Cream; Topical,
                          100,000 units/g.
ANDA 060578............  MYCOSTATIN (nystatin)    Do.
                          Powder; Topical
                          100,000 units/g.
ANDA 063116............  TOBRAMYCIN SULFATE       Hospira, Inc.
                          (PHARMACY BULK)
                          (tobramycin sulfate)
                          Injectable; Injection,
                          EQ 40 mg base/
                          milliliter.
------------------------------------------------------------------------

    FDA has reviewed its records and, under Sec.  314.161, has 
determined that the drug products listed in this document were not 
withdrawn from sale for reasons of safety or effectiveness. 
Accordingly, the Agency will continue to list the drug products listed 
in this document in the ``Discontinued Drug Product List'' section of 
the Orange Book. The ``Discontinued Drug Product List'' identifies, 
among other items, drug products that have been discontinued from 
marketing for reasons other than safety or effectiveness.
    Approved ANDAs that refer to the NDAs and ANDAs listed in this 
document are unaffected by the discontinued marketing of the products 
subject to those NDAs and ANDAs. Additional ANDAs that refer to these 
products may also be approved by the Agency if they comply with 
relevant legal and regulatory requirements. If FDA determines that 
labeling for these drug products should be revised to meet current 
standards, the Agency will advise ANDA applicants to submit such 
labeling.

    Dated: November 30, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-30628 Filed 12-3-15; 8:45 am]
 BILLING CODE 4164-01-P